Edition:
India

Walgreens Boots Alliance Inc (WBA.OQ)

WBA.OQ on NASDAQ Stock Exchange Global Select Market

55.30USD
18 Oct 2019
Change (% chg)

$-0.64 (-1.14%)
Prev Close
$55.94
Open
$56.02
Day's High
$56.17
Day's Low
$55.27
Volume
2,042,221
Avg. Vol
1,875,920
52-wk High
$86.29
52-wk Low
$49.03

Latest Key Developments (Source: Significant Developments)

Kroger And Walgreens To Expand Exploratory Pilot To Knoxville, Tennessee
Monday, 19 Aug 2019 

Aug 19 (Reuters) - Walgreens Boots Alliance Inc ::KROGER AND WALGREENS TO EXPAND EXPLORATORY PILOT TO KNOXVILLE, TENNESSEE.CO, WALGREENS INTRODUCE NEW TEST AREA FOR RETAILERS, FEATURING EXPANSION OF KROGER EXPRESS AND KROGER PICKUP AT SELECT WALGREENS STORES.CO, WALGREENS INTRODUCE NEW TEST AREA FOR RETAILERS, FEATURING LAUNCH OF WALGREENS' OWNED-BRAND HEALTH & BEAUTY PRODUCTS IN 17 KROGER STORES.  Full Article

Walgreens Boots Alliance Says On August 9, Entered Amendment No. 1 To Term Loan Credit Agreement Amending Credit Agreement Dated Dec 5, 2018
Monday, 12 Aug 2019 

Aug 12 (Reuters) - Walgreens Boots Alliance Inc ::WALGREENS BOOTS ALLIANCE - ON AUGUST 9, ENTERED AMENDMENT NO. 1 TO TERM LOAN CREDIT AGREEMENT AMENDING CREDIT AGREEMENT DATED DEC 5, 2018.WALGREENS BOOTS ALLIANCE - CREDIT AGREEMENT WAS AMENDED TO PERMIT CO TO BORROW, REPAY & REBORROW AMOUNTS BORROWED THEREUNDER PRIOR TO MATURITY DATE.  Full Article

Healthy.Io Enters Agreement With Walgreens Boots Alliance to Place Healthy.Io's Dip UTI Test Kits In Boots Pharmacies Throughout United Kingdom
Wednesday, 17 Jul 2019 

July 17 (Reuters) - Healthy.Io::HEALTHY.IO - AGREEMENT WITH WALGREENS BOOTS ALLIANCE, PLACING HEALTHY.IO'S DIP UTI TEST KITS IN HUNDREDS OF BOOTS PHARMACIES THROUGHOUT UNITED KINGDOM.  Full Article

Altaire Pharma Issues Voluntary Recall Of Multiple Ophthalmic Products Sold At Walgreens
Thursday, 4 Jul 2019 

July 3 (Reuters) - ALTAIRE PHARMACEUTICALS::ALTAIRE PHARMACEUTICALS, INC. ISSUES VOLUNTARY RECALL OF MULTIPLE OPHTHALMIC PRODUCTS SOLD AT WALGREENS.ALTAIRE PHARMACEUTICALS - INITIATING RECALL DUE TO MANAGEMENT CONCERNS REGARDING SUFFICIENCY OF QUALITY ASSURANCE CONTROLS.ALTAIRE PHARMACEUTICALS - RECALLED PRODUCTS ARE MANUFACTURED & LABELED EXCLUSIVELY FOR WALGREENS.  Full Article

Boots The Chemist, Chain Owned By Walgreens Boots Alliances, Is Considering Closing More Than 200 Shops - Sky News
Tuesday, 28 May 2019 

May 28 (Reuters) - :BOOTS THE CHEMIST, CHAIN OWNED BY WALGREENS BOOTS ALLIANCES, IS CONSIDERING CLOSING MORE THAN 200 SHOPS - SKY NEWS.  Full Article

Walgreens Says Reimbursement Pressure Will Subside In Second Half Of 2019
Tuesday, 2 Apr 2019 

April 2 (Reuters) - Walgreens Boots Alliance Inc ::CFO SAYS PHARMACY MARKET IS VERY CHALLENGING RIGHT NOW AND WE ARE SEEING SIMILAR TRENDS WITH RIVALS - CONF CALL.EXEC SAYS UNDERTAKING COMPREHENSIVE REVIEW OF WALGREENS STORE NETWORKS TO IDENTIFY UNDERPERFORMING STORES - CONF CALL.EXEC SAYS WE ANTICIPATE GROSS MARGINS TO REMAIN UNDER PRESSURE IN THE US IN THE SECOND HALF OF 2019 - CONF CALL.CFO - "OVER THE LONG TERM, WE ARE COMFORTABLE THAT OUR GROWTH MODEL CAN DELIVER MID- TO HIGH SINGLE-DIGIT ADJUSTED EPS GROWTH IN CONSTANT CURRENCIES" - CONF CALL.EXEC SAYS REIMBURSEMENT PRESSURE WILL SUBSIDE IN THE SECOND HALF OF 2019 - CONF CALL.  Full Article

Walgreens Boots Alliance Reports Q2 Adjusted Earnings Per Share Of $1.64
Tuesday, 2 Apr 2019 

April 2 (Reuters) - Walgreens Boots Alliance Inc ::WALGREENS BOOTS ALLIANCE REPORTS FISCAL 2019 SECOND QUARTER RESULTS.Q2 ADJUSTED EARNINGS PER SHARE $1.64.Q2 EARNINGS PER SHARE $1.24.Q2 EARNINGS PER SHARE ESTIMATE $1.72 -- REFINITIV IBES DATA.QTRLY SALES INCREASED 4.6 PERCENT TO $34.5 BILLION.RETAIL PHARMACY USA HAD Q2 SALES OF $26.3 BILLION, AN INCREASE OF 7.3 PERCENT OVER YEAR-AGO QUARTER.COMPANY INCREASED TARGETED ANNUAL COST SAVINGS FROM IN EXCESS OF $1 BILLION TO IN EXCESS OF $1.5 BILLION BY FISCAL 2022.FISCAL 2019 ADJUSTED EPS GROWTH EXPECTED TO BE ROUGHLY FLAT AT CONSTANT CURRENCY RATES.RETAIL PHARMACY INTERNATIONAL HAD Q2 SALES OF $3.1 BILLION, A DECREASE OF 7.1 PERCENT FROM YEAR-AGO QUARTER.INCREASED TARGETED ANNUAL COST SAVINGS FROM IN EXCESS OF $1 BILLION TO IN EXCESS OF $1.5 BILLION BY FISCAL 2022.DURING QUARTER, WE SAW SIGNIFICANT REIMBURSEMENT PRESSURE, COMPOUNDED BY LOWER GENERIC DEFLATION.DURING QUARTER SAW CONTINUED CONSUMER MARKET CHALLENGES IN U.S. AND UK.WALGREENS - MARKET CHALLENGES & MACRO TRENDS ACCELERATED, RESULTING IN MOST DIFFICULT QUARTER WE HAVE HAD SINCE FORMATION OF CO.WHILE CO HAD BEGUN INITIATIVES TO ADDRESS TRENDS, RESPONSE WAS NOT RAPID ENOUGH GIVEN MARKET CONDITIONS.FOR RETAIL PHARMACY USA, COMPARABLE RETAIL SALES WERE DOWN 3.8 PERCENT IN THE QUARTER.WE ARE GOING TO BE "MORE AGGRESSIVE" IN RESPONSE TO RAPIDLY SHIFTING TRENDS.AS A RESULT OF QUARTER, ARE NOW EXPECTING ROUGHLY FLAT ADJUSTED EPS GROWTH FOR FISCAL 2019..  Full Article

Concepta To Supply MyLotus Product To Boots UK
Friday, 29 Mar 2019 

March 29 (Reuters) - Concepta PLC ::AGREED TO SUPPLY MYLOTUS PRODUCT FOR WOMEN'S FERTILITY AND HORMONE TESTING TO BOOTS UK, A MEMBER OF WALGREENS BOOTS ALLIANCE.  Full Article

Valoremrx Collaborates With Kroger Specialty Pharmacy To Improve Access And Patient Care
Tuesday, 19 Mar 2019 

March 19 (Reuters) - Walgreens Boots Alliance Inc ::VALOREMRX COLLABORATES WITH KROGER SPECIALTY PHARMACY TO IMPROVE ACCESS AND PATIENT CARE.VALOREMRX SPECIALTY SOLUTIONS-THE GPO FORMED BY JV BETWEEN EXPRESS SCRIPTS & WALGREENS, ANNOUNCED ITS NEW COLLABORATION WITH KROGER SPECIALTY PHARMACY.  Full Article

BioScrip And Option Care To Merge
Friday, 15 Mar 2019 

March 15 (Reuters) - BioScrip Inc ::PRESS RELEASE - HOME AND ALTERNATE SITE INFUSION THERAPY PROVIDERS BIOSCRIP AND OPTION CARE TO MERGE.BIOSCRIP INC - BIOSCRIP TO ISSUE NEW SHARES TO OPTION CARE'S SHAREHOLDER, WHICH WILL OWN APPROXIMATELY 80% OF COMBINED COMPANY ON FULLY DILUTED BASIS.BIOSCRIP INC - COMBINED COMPANY'S COMMON STOCK WILL CONTINUE TO BE LISTED ON NASDAQ GLOBAL MARKET.BIOSCRIP INC - TRANSACTION HAS BEEN UNANIMOUSLY APPROVED BY BOARDS OF DIRECTORS OF BOTH BIOSCRIP AND OPTION CARE.BIOSCRIP INC - COMBINED CO WILL BE LED BY OPTION CARE CHIEF EXECUTIVE OFFICER JOHN RADEMACHER AND OPTION CARE CHIEF FINANCIAL OFFICER MIKE SHAPIRO.BIOSCRIP INC - CO'S PRESIDENT AND CEO DANIEL E. GREENLEAF WILL REMAIN ACTIVE IN COMBINED CO AS A SPECIAL ADVISOR TO ITS BOARD OF DIRECTORS.BIOSCRIP - CO,OPTION CARE SECURED COMMITTED FINANCING FROM BANK OF AMERICA MERRILL LYNCH, FUNDS AFFILIATED WITH ARES MANAGEMENT, GOLDMAN SACHS MERCHANT BANKING DIVISION.BIOSCRIP - CO,OPTION CARE SECURED COMMITTED FINANCING TO REFINANCE & SIMPLIFY COMBINED CO'S CAPITAL STRUCTURE.BIOSCRIP - CO TO ISSUE NEW SHARES TO OPTION CARE'S SHAREHOLDER, OWNED BY INVESTMENT FUNDS RELATED TO MADISON DEARBORN PARTNERS, & WALGREENS BOOTS ALLIANCE.  Full Article

Photo

Sanofi pulls Zantac from U.S. and Canada after carcinogen found

NEW YORK Sanofi SA said on Friday it would recall popular heartburn medicine Zantac in the United States and Canada, after the medicines were linked with a probable cancer-causing impurity.